17 assets in Interstitial Lung Disease

Therapeutic assets addressing Interstitial Lung Disease, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Uniprost Interstitial Lung Disease	United Therapeutics	P3	BB (64)
Cyclophosphamide Interstitial Lung Disease	Intergroupe Francophone de Cancerologie Thoracique	P2/3	B (63)
[68ga]cbp8 Interstitial Lung Disease	Peter Caravan	P2	CCC (53)
Bio 300 Interstitial Lung Disease	Memorial Sloan Kettering Cancer Center	P2	CCC (53)
Carboplatin Interstitial Lung Disease	Intergroupe Francophone de Cancerologie Thoracique	P2	CCC (53)
Catequentinib Interstitial Lung Disease	First Affiliated Hospital of Wenzhou Medical University	P2	CCC (53)
Hymecromone Interstitial Lung Disease	National Institute of Environmental Health Sciences (NIEHS)	P2	CCC (53)
Nivolumab Interstitial Lung Disease	Intergroupe Francophone de Cancerologie Thoracique	P2	CCC (53)
Pembrolizumab Interstitial Lung Disease	Intergroupe Francophone de Cancerologie Thoracique	P2	CCC (53)
Senicapoc Interstitial Lung Disease	Vejle Hospital	P2	CCC (53)
Tofacitinib Interstitial Lung Disease	National Institute of Respiratory Diseases, Mexico	P2	CCC (53)
Vinorelbine Ditartrate Interstitial Lung Disease	Intergroupe Francophone de Cancerologie Thoracique	P2	CCC (53)
XENON Interstitial Lung Disease	Thunder Bay Regional Health Research Institute	P1	CCC (48)
Semaglutide Interstitial Lung Disease	University of Pennsylvania	P1/2	CC (47)
Nintedanib Interstitial Lung Disease	Shenzhen Resproly Biopharmaceutical Co., Ltd	P1	CC (43)
Fapi-46 Interstitial Lung Disease	University of California, Los Angeles	Early P1	C (39)
rsn0402 part 1 Interstitial Lung Disease	Shenzhen Resproly Biopharmaceutical Co., Ltd	P1	NR ()